{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T17:42:19Z","timestamp":1783359739969,"version":"3.54.6"},"reference-count":30,"publisher":"Royal College of Psychiatrists","issue":"5","license":[{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec id=\"S0007125024001041_sec_a1\"><jats:title>Background<\/jats:title><jats:p>Clozapine is the most effective antipsychotic for treatment-resistant psychosis. However, clozapine is underutilised in part because of potential agranulocytosis. Accumulating evidence indicates that below-threshold haematological readings in isolation are not diagnostic of life-threatening clozapine-induced agranulocytosis (CIA).<\/jats:p><\/jats:sec><jats:sec id=\"S0007125024001041_sec_a2\"><jats:title>Aims<\/jats:title><jats:p>To examine the prevalence and timing of CIA using different diagnostic criteria and to explore demographic differences of CIA in patients registered on the UK Central Non-Rechallenge Database (CNRD).<\/jats:p><\/jats:sec><jats:sec id=\"S0007125024001041_sec_a3\" sec-type=\"methods\"><jats:title>Method<\/jats:title><jats:p>We analysed data of all patients registered on the UK Clozaril<jats:sup>\u00ae<\/jats:sup> Patient Monitoring Service Central Non-Rechallenge Database (at least one absolute neutrophil count (ANC) &lt; 1.5 \u00d7 10<jats:sup>9<\/jats:sup>\/L and\/or white blood cell count &lt; 3.0 \u00d7 10<jats:sup>9<\/jats:sup>\/L) between May 2000 and February 2021. We calculated prevalence rates of agranulocytosis using threshold-based and pattern-based criteria, stratified by demographic factors (gender, age and ethnicity). Differences in epidemiology based on rechallenge status and clozapine indication were explored. The proportion of patients who recorded agranulocytosis from a normal ANC was explored.<\/jats:p><\/jats:sec><jats:sec id=\"S0007125024001041_sec_a4\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>Of the 3029 patients registered on the CNRD with 283 726 blood measurements, 593 (19.6%) were determined to have threshold-based agranulocytosis and 348 (11.4%) pattern-based agranulocytosis. In the total sample (75 533), the prevalence of threshold-based agranulocytosis and pattern-based agranulocytosis was 0.8% and 0.5%, respectively. The median time to threshold-based agranulocytosis was 32 weeks (IQR 184) and 15 (IQR 170) weeks for pattern-based agranulocytosis. Among age groups, the prevalence of pattern-based agranulocytosis and threshold-based agranulocytosis was highest in the &gt;48 age group. Prevalence rates were greatest for White (18%) and male individuals (13%), and lowest for Black individuals (0.1%). The proportion of people who were determined to have pattern-based agranulocytosis without passing through neutropenia was 70%.<\/jats:p><\/jats:sec><jats:sec id=\"S0007125024001041_sec_a5\" sec-type=\"conclusions\"><jats:title>Conclusions<\/jats:title><jats:p>Threshold-based definition of agranulocytosis may over-diagnose CIA. Monitoring schemes should take into consideration neutrophil patterns to correctly identify clinically relevant CIA. In marked contrast to previous studies, CIA occurred least in Black individuals and most in White individuals.<\/jats:p><\/jats:sec>","DOI":"10.1192\/bjp.2024.104","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T08:35:17Z","timestamp":1723797317000},"page":"484-491","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":14,"title":["Identifying clinically relevant agranulocytosis in people registered on the UK clozapine Central Non-Rechallenge Database: retrospective cohort study"],"prefix":"10.1192","volume":"225","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1352-4017","authenticated-orcid":false,"given":"Ebenezer","family":"Oloyede","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7526-2660","authenticated-orcid":false,"given":"Christian J.","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3878-2143","authenticated-orcid":false,"given":"Olubanke","family":"Dzahini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Miguel","family":"Lopez Alcaraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaurya Dev","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalliopi","family":"Vallianatu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhardt","family":"Funk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6146-0073","authenticated-orcid":false,"given":"Eromona","family":"Whiskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2557-1710","authenticated-orcid":false,"given":"David","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2024,8,16]]},"reference":[{"key":"S0007125024001041_ref10","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1017\/S204579602200066X","article-title":"Clozapine haematological monitoring for neutropenia: a global perspective","volume":"31","author":"Oloyede","year":"2022","journal-title":"Epidemiol Psychiatr Sci"},{"key":"S0007125024001041_ref12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/acps.12898","article-title":"Meta-analysis examining the epidemiology of clozapine-associated neutropenia","volume":"138","author":"Myles","year":"2018","journal-title":"Acta Psychiatr Scand"},{"key":"S0007125024001041_ref2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/YIC.0b013e32836508e6","article-title":"The social and economic burden of treatment-resistant schizophrenia: a systematic literature review","volume":"29","author":"Kennedy","year":"2014","journal-title":"Int Clin Psychopharmacol"},{"key":"S0007125024001041_ref6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1192\/bjb.2018.67","article-title":"Barriers to using clozapine in treatment-resistant schizophrenia: systematic review","volume":"43","author":"Farooq","year":"2019","journal-title":"BJPsych Bull"},{"key":"S0007125024001041_ref7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/0957154X07070335","article-title":"The history of clozapine and its emergence in the US market: a review and analysis","volume":"18","author":"Crilly","year":"2007","journal-title":"History Psychiatry"},{"key":"S0007125024001041_ref18","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJM199307153290303","article-title":"Clozapine-induced agranulocytosis. Incidence and risk factors in the United States","volume":"329","author":"Alvir","year":"1993","journal-title":"N Engl J Med"},{"key":"S0007125024001041_ref17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41537-022-00232-0","article-title":"Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis","volume":"8","author":"Taylor","year":"2022","journal-title":"NPJ Schizophr"},{"key":"S0007125024001041_ref19","first-page":"233","article-title":"Blood dyscrasias in clozapine-treated patients in Italy","volume":"85","author":"Deliliers","year":"2000","journal-title":"Haematologica"},{"key":"S0007125024001041_ref24","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1192\/bjp.169.4.483","article-title":"Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland","volume":"169","author":"Atkin","year":"1996","journal-title":"Br J Psychiatry"},{"key":"S0007125024001041_ref28","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1136\/bmj.2.5052.1048","article-title":"Chlorpromazine jaundice","volume":"2","author":"Lambo","year":"1957","journal-title":"BM J"},{"key":"S0007125024001041_ref26","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1055\/s-2004-815513","article-title":"Blood dyscrasias induced by psychotropic drugs","volume":"37","author":"St\u00fcbner","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"S0007125024001041_ref30","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/JCP.0000000000000767","article-title":"The use of granulocyte colony-stimulating factor in clozapine rechallenge: a systematic review","volume":"37","author":"Lally","year":"2017","journal-title":"J Clin Psychopharmacol"},{"key":"S0007125024001041_ref1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes","year":"2017","journal-title":"Am J Psychiatry"},{"key":"S0007125024001041_ref5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/acps.12742","article-title":"International trends in clozapine use: a study in 17 countries","volume":"136","author":"Bachmann","year":"2017","journal-title":"Acta Psychiatr Scand"},{"key":"S0007125024001041_ref25","doi-asserted-by":"crossref","first-page":"20451253211072341","DOI":"10.1177\/20451253211072341","article-title":"Clozapine-and non-clozapine-associated neutropenia in patients with schizophrenia: a retrospective cohort study","volume":"12","author":"Johannsen","year":"2022","journal-title":"Ther Adv Psychopharmacol"},{"key":"S0007125024001041_ref13","doi-asserted-by":"crossref","DOI":"10.1016\/S2215-0366(22)00188-2","article-title":"Relaxation of the criteria for entry to the UK clozapine Central Non-Rechallenge Database: a modelling study","volume":"9","author":"Oloyede","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"S0007125024001041_ref9","article-title":"Patients\u2019 experiences of clozapine for treatment-resistant schizophrenia: a systematic review","volume":"3","author":"Parkes","year":"2022","journal-title":"Schizophr BullOpen"},{"key":"S0007125024001041_ref3","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1177\/0706743717718167","article-title":"Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis","volume":"62","author":"Siskind","year":"2017","journal-title":"Can J Psychiatry"},{"key":"S0007125024001041_ref20","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1192\/bjp.175.6.576","article-title":"Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance","volume":"175","author":"Munro","year":"1999","journal-title":"Br J Psychiatry"},{"key":"S0007125024001041_ref27","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1089\/cap.2011.0136","article-title":"Risk factors for neutropenia in clozapine-treated children and adolescents with childhood-onset schizophrenia","volume":"23","author":"Maher","year":"2013","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"S0007125024001041_ref16","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ajh.10295","article-title":"Neutropenia and agranulocytosis in England and Wales: incidence and risk factors","volume":"72","author":"van Staa","year":"2003","journal-title":"Am J Hematol"},{"key":"S0007125024001041_ref4","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"S0007125024001041_ref21","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/schbul\/sbab006","article-title":"There is life after the UK clozapine Central Non-Rechallenge Database","volume":"47","author":"Oloyede","year":"2021","journal-title":"Schizophr Bull"},{"key":"S0007125024001041_ref14","doi-asserted-by":"crossref","first-page":"e909","DOI":"10.4088\/JCP.15r10085","article-title":"Benign ethnic neutropenia and clozapine use: a systematic review of the evidence and treatment recommendations","volume":"77","author":"Manu","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"S0007125024001041_ref22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41537-022-00232-0","article-title":"Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis","volume":"8","author":"Taylor","year":"2022","journal-title":"Schizophrenia"},{"key":"S0007125024001041_ref29","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/schbul\/sbab103","article-title":"Reducing the risk of withdrawal symptoms and relapse following clozapine discontinuation\u2014is it feasible to develop evidence-based guidelines?","volume":"48","author":"Blackman","year":"2022","journal-title":"Schizophr Bull"},{"key":"S0007125024001041_ref15","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1001\/jamapsychiatry.2023.0376","article-title":"International variation in clozapine hematologic monitoring \u2013 a call for action","volume":"80","author":"Oloyede","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"S0007125024001041_ref8","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1017\/S0033291719000369","article-title":"The prevalence of agranulocytosis and related death in clozapine-treated patients: a comprehensive meta-analysis of observational studies","volume":"50","author":"Li","year":"2020","journal-title":"Psychol Med"},{"key":"S0007125024001041_ref11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/0004867419833166","article-title":"A meta-analysis of controlled studies comparing the association between clozapine and other antipsychotic medications and the development of neutropenia","volume":"53","author":"Myles","year":"2019","journal-title":"Aust N Z J Psychiatry"},{"key":"S0007125024001041_ref23","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41592-019-0686-2","article-title":"Scipy 1.0: fundamental algorithms for scientific computing in Python","volume":"17","author":"Virtanen","year":"2020","journal-title":"Nat Methods"}],"container-title":["The British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125024001041","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T19:16:51Z","timestamp":1733944611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125024001041\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,16]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0007125024001041"],"URL":"https:\/\/doi.org\/10.1192\/bjp.2024.104","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,16]]},"assertion":[{"value":"Copyright \u00a9 The Author(s), 2024. Published by Cambridge University Press on behalf of Royal College of Psychiatrists","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0), which permits non-commercial re-use, distribution, and reproduction in any medium, provided that no alterations are made and the original article is properly cited. The written permission of Cambridge University Press must be obtained prior to any commercial use and\/or adaptation of the article.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}